Nav: Home

Aspirin may help some breast cancer survivors, but changes in DNA may mean harm for others

August 12, 2019

Previous studies have shown that some women who use aspirin and are later diagnosed with breast cancer may live longer, which may be related to the drug's anti-inflammatory effects on the body. However, a portion of aspirin users with breast cancer appeared to have a higher risk of mortality following breast cancer. According to a new study from researchers at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, the reason for this reverse effect could be explained by DNA methylation of genes in breast cancer tumors or peripheral blood.

Methylation is a chemical modification wherein a methyl group acts like light switches along the DNA molecule, turning some genetic activity on and some off. Chemical shifts in areas of DNA that are responsible for cell death, damage and repair - such as occurs in methylation - are known contributors to the development of cancer over time. Identifying the areas where these epigenetic changes take place show promise in predicting certain risks or effective methods of treatment.

The study, published on Aug. 12 in the American Cancer Society's interdisciplinary journal CANCER, is the first to examine the effect of DNA methylation in breast tumor tissues and cells circulating in the patients' peripheral blood on the association between aspirin use and mortality in women with breast cancer.

"Chronic inflammation is a key player in the development of multiple cancer types, including breast cancer," said first author Tengteng Wang, who led this study while she was a doctoral candidate in the epidemiology department at the Gillings School. "Aspirin is a major non-steroidal anti-inflammatory drug which has anti-inflammatory properties. Given this, substantial evidence from laboratory and population studies suggests that taking aspirin may reduce the risk of developing breast cancer."

However, the association of aspirin use with death outcomes following breast cancer diagnosis remains inconclusive and inconsistent across studies, which prompted the researchers to explore whether aspirin's varying influences on breast cancer patients could be related to distinctly different DNA profiles due to methylation.

The team analyzed data from 1,266 women with breast cancer in the Long Island Breast Cancer Study who were followed for subsequent mortality. All-cause mortality after breast cancer was elevated by 67% among those who had used aspirin at least once a week for six weeks pre-diagnosis and had a methylated tumor promotor of breast cancer gene 1, known as BRCA1. Breast cancer-specific mortality decreased by 22-40% in aspirin users with unmethylated tumor promoter of BRCA1 and progesterone receptor (PR) genes, and also those with long interspersed elements-1 global hypermethylation. These results suggest real differences in breast cancer mortality risk in patient groups with these different methylation profiles in tumor tissue DNA and peripheral blood DNA.

The research team points to the need for further exploration of the potential impact - good or bad - aspirin may have on specific breast cancer patients due to their DNA methylation profiles. The findings do not indicate that anyone with elevated breast cancer risk should start taking aspirin, and people should speak to their doctors before they make changes to their medications.

"Future research designed to replicate our findings should include a larger sample size to allow examination of patterns of aspirin use, and an enlarged panel of genes to explore the role of genetic predisposition in driving overall genetic instability on survival after breast cancer diagnosis," said Wang and her mentor Marilie Gammon, a professor of epidemiology at the Gillings School and senior author on the study.
-end-
This study was funded in part by grants from the National Institutes of Health and in collaboration with researchers at Emory University, University of California at Berkeley, University of Montana, Columbia University and Icahn School of Medicine at Mount Sinai, as well as Roche Product Development in Asia-Pacific in Shanghai, China, and the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina.

Tengteng Wang is currently a postdoctoral researcher at Harvard University and Brigham and Women's Hospital.

About the University of North Carolina at Chapel Hill

The University of North Carolina at Chapel Hill, the nation's first public university, is a global higher education leader known for innovative teaching, research and public service. A member of the prestigious Association of American Universities, Carolina regularly ranks as the best value for academic quality in U.S. public higher education. Now in its third century, the University offers 74 bachelor's, 104 master's, 65 doctorate and seven professional degree programs through 14 schools including the College of Arts & Sciences. Every day, faculty, staff and students shape their teaching, research and public service to meet North Carolina's most pressing needs in every region and all 100 counties. Carolina's nearly 336,000 alumni live in all 50 states, the District of Columbia, U.S. Territories and 164 countries. More than 178,000 live in North Carolina.

University of North Carolina at Chapel Hill

Related Science Articles:

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.
AAAS and March for Science partner to uphold science
AAAS, the world's largest general scientific organization, announced Thursday that it will partner with the March for Science, a nonpartisan set of activities that aim to promote science education and the use of scientific evidence to inform policy.
Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.
Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.
More Science News and Science Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...